Featured
Recent
COVID-19
October 19, 2022
Patients need support when it comes to adopting and sustaining healthy behaviors. Over half of the adults in the United States have at least one chronic disease and 25 percent have two or more. Yet, providers seldom learn how to counsel patients on healthy living and, even if they do, they have limited time to guide patients to make lasting change.
Presented by: Gerald Lemole, MD
“The Role of Lymphstasis in Atherogenesis” appeared in the Annals of Thoracic Surgery in the March 1981 issue. It examined the significance of lymphatic involvement in arteriosclerosis. Presently, the underlying premise of the original paper is reviewed with its relationship to recent information regarding reverse cholesterol transport.
Small Intestine Bacterial Overgrowth - Key Elements Regarding Testing and Intervention
Presented by: Betsy Redmond, PhD, MMSc, RDN
Integrative and Functional Medicine has laid significant groundwork for providing a format to apply metabolomics in practice, though it has been slow to incorporate newer findings. As the clinical application of metabolomics gains support, clinicians must ensure they understand the level of evidence of individual markers, of key pathways, nutrient-cofactors, enzymes, genes, and key patterns of disease. This talk will review newer findings in metabolomics research such as patterns of metabolic disease and impacts of physiologic functions. A metabolomic signature is the combination of metabolites that describe an individual’s core metabolomic state combined with the impacts of lifestyle, medications, physiology, and other key factors.
Integrative Practitioner is pleased to offer the Complete Conference Package, featuring all session recordings from the at the 2022 Integrative Healthcare Symposium in New York City. Watch and listen on your own schedule as the most sought-after practitioners, researchers, and educators of integrative healthcare offer their latest research and findings. Stay on the cutting edge of integrative healthcare and discover the latest practical applications to immediately enhance your practice.
The current state of medical therapy for cognitive decline and dementia is focused on single drug therapy. This approach has yielded unsatisfactory outcomes. A Functional Medicine approach utilizes a model of evaluation and therapeutics that is an assessment of the bioterrain of the unique individual in relation their individual genetics interaction with their environmental exposome to assess and provide a personalized, precision approach to brain health based on each individual’s genetics, the unique epigenetic triggers, the exacerbating hormone and nutritional imbalances as well as the deficiencies in optimal assimilation and biotransformation. Potential hormone imbalances, nutrient deficiencies combined with unique toxic insults may potentiate these processes leading to poor cognitive outcomes.
Presented by: Lorraine Gahles-Kildow, PhD and Nancy Gahles DC, CCH, MBSR
Stress in the healthcare profession has reached epidemic proportions. Physician burnout is on the rise. Almost half of doctors experience at least one symptom of burnout and one third of intensive care unit nurses suffer from severe Burnout Syndrome (BOS) associated with stress. Caregivers, professional and those in family situations caring for parents, partners, and special needs children, often suffer undiagnosed BOS from stress.
Presented by: Tereza Hubkov, MD
As pharmaceuticals continue to be disappointing when it comes to prevention or treatment of dementia, or they are plagued with significant side effects, it is time to return to the many natural treatments used by our ancestors for many centuries and now increasingly more validated by modern research. Adaptogenic, nootropic plants, mushrooms, foods and culinary spices have shown significant ability to minimize the pathology of Alzheimer’s dementia, Parkinson’s disease, and other brain health disorders. In this session, participants will learn about the health benefits and safety of Ashwagandha, Reishi, Rhodiola, Schizandra, Lion’s mane, Bacopa, turmeric, garlic, sage, and cinnamon, to name just a few of nature’s broad apothecary.
In 1996, the question originated from Dr. Eli A Friedman’s article, “can the Bowel act as a kidney substitute in advance renal failure?” prior to the discovery of the gut microbiome. The bowel was recognized as an organ in 2004 in Proceedings of the National Academy of Science. Advances in bioinformatics led to further understanding of the human gut microbiome. Exponential advances in technology led to a greater knowledge and understanding of the gut microbiomes’ role in health, and disease. The knowledge gained, lead to further understanding of the term dysbiosis (an imbalance of pathogenic gut bacteria). Now, dysbiosis is universally documented as the prime cause for various diseases. The connection between the gut and CKD became evident with the cover article in the Sept/2012 issue of Kidney International. Followed by, the publication of a similar article in Clinical Kidney Journal in 2015. In 1997 Enteric Dialysis® was transformed from a concept into a reality, by Dr. Ranganathan and his research team at Kibow Biotech Inc. After 20 years of R&D, Kibow has used clinical findings of pro/prebiotics to modulate the gut microbiome to improve clinical outcomes in CKD patients worldwide.